— Know what they know.
Not Investment Advice
Also trades as: 0HOH.L (LSE) · $vol 0M

BLUE NASDAQ

bluebird bio, Inc.
1W: -0.4% 1M: +22.7% 3M: +28.1% 1Y: -72.4% 3Y: -91.7% 5Y: -99.4%
$4.97
Last traded 2025-06-02 — delisted
NASDAQ · Healthcare · Biotechnology · $48.7M mcap · 10M float · 5.93% daily turnover · Short 39% of daily vol

Revenue Segmentation

By Product / Service

Revenue by Segment (5-Year Trend)

Income Trends

Revenue
$84M +184.1% ▲
5Y CAGR: +13.4%
Gross Profit
-$6M -38.3% ▼
Operating Income
-$270M -10.7% ▼
Net Income
-$241M -13.6% ▼
EPS (Diluted)
$-24.84 -736.4% ▼
EBITDA
-$157M +6.2% ▲

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2020FY2021FY2022FY2023FY2024
Revenue$251M$4M$4M$29M$84M
YoY Growth+461.3%-98.5%-1.8%+720.0%+184.1%
Cost of Revenue$5M$39M$10M$34M$89M
Gross Profit$245M-$35M-$6M-$4M-$6M
Gross Margin97.8%-961.1%-180.2%-13.7%-6.6%
R&D Expenses$319M$320M$241M$168M$94M
SG&A Expenses$240M$210M$137M$166M$168M
Operating Expenses$875M$556M$244M$240M$265M
Operating Income-$559M-$591M-$250M-$244M-$270M
Operating Margin-223.0%-16136.3%-6955.4%-828.1%-322.7%
Interest Expense$0$0$6M$16M$23M
Income Before Tax-$560M-$562M-$230M-$212M-$241M
Tax Expense$686K$258K$117K-$126K$70K
Net Income-$619M-$819M-$230M-$212M-$241M
Net Margin-246.8%-22375.2%-6403.7%-718.4%-287.2%
EPS (Diluted)$-9.95$-8.16$-3.39$-2.97$-24.84
EBITDA-$554M-$557M-$216M-$167M-$157M
Shares Outstanding62M69M79M71M10M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms